New Study Reveals How Protein Hydrolysates Could Protect Newborns' Fragile Guts

A new study by S.J. McElroy, set for publication in Pediatric Research in 2026, examines how extensive protein hydrolysates (EPHs) could strengthen the fragile intestines of newborns. The research focuses on improving gut health in vulnerable infants, where immature intestinal barriers often lead to complications in neonatal care. EPHs are created by breaking down whole proteins into smaller peptides and amino acids. This process reduces the risk of allergic reactions while making them easier to digest. McElroy’s team found that certain peptide fragments from EPHs boost the production of claudins and occludins—proteins essential for sealing gaps between intestinal cells. By restoring this barrier, the peptides help lower inflammation and protect against infections.

The study combined lab-grown epithelial cell models with tests on neonatal animals to track how EPHs affect gut health. Results showed that these hydrolysates not only tighten cell junctions but also encourage the growth of beneficial gut bacteria. They also trigger immune cells in the gut-associated lymphoid tissue (GALT) to release anti-inflammatory signals while blocking harmful ones. Beyond structural repairs, EPHs appear to speed up the healing of damaged intestinal lining in premature or sick infants. McElroy suggests adding them to specialised feeding formulas for high-risk newborns. However, the research notes hurdles like production costs, taste acceptance, and the need for standardised hydrolysate quality before widespread use. The paper concludes with a call for larger clinical trials to confirm safety and effectiveness in human neonates.

If adopted, EPH-fortified formulas could offer a practical way to reinforce intestinal defences in fragile infants. The findings highlight a promising step toward reducing gut-related complications in neonatal units. Further testing will determine how soon these hydrolysates might enter routine clinical practice.